MX2013007146A - Agentes de proteina f/i de membrana externa (oprf/i) y su uso en pacientes hospitalizados y otros pacientes. - Google Patents
Agentes de proteina f/i de membrana externa (oprf/i) y su uso en pacientes hospitalizados y otros pacientes.Info
- Publication number
- MX2013007146A MX2013007146A MX2013007146A MX2013007146A MX2013007146A MX 2013007146 A MX2013007146 A MX 2013007146A MX 2013007146 A MX2013007146 A MX 2013007146A MX 2013007146 A MX2013007146 A MX 2013007146A MX 2013007146 A MX2013007146 A MX 2013007146A
- Authority
- MX
- Mexico
- Prior art keywords
- oprf
- hospitalized
- patients
- agents
- carboxy
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- KKEBXNMGHUCPEZ-UHFFFAOYSA-N 4-phenyl-1-(2-sulfanylethyl)imidazolidin-2-one Chemical compound N1C(=O)N(CCS)CC1C1=CC=CC=C1 KKEBXNMGHUCPEZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010058634 Bacteria outer membrane lipoprotein I Proteins 0.000 abstract 1
- 101710203389 Outer membrane porin F Proteins 0.000 abstract 1
- 101710160104 Outer membrane protein F Proteins 0.000 abstract 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/104—Pseudomonadales, e.g. Pseudomonas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061426760P | 2010-12-23 | 2010-12-23 | |
| PCT/EP2011/054127 WO2012084272A1 (en) | 2010-12-23 | 2011-03-18 | Oprf/i agents and their use in hospitalized and other patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013007146A true MX2013007146A (es) | 2013-11-01 |
Family
ID=44210049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013007146A MX2013007146A (es) | 2010-12-23 | 2011-03-18 | Agentes de proteina f/i de membrana externa (oprf/i) y su uso en pacientes hospitalizados y otros pacientes. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130266575A1 (enExample) |
| EP (1) | EP2655402A1 (enExample) |
| JP (2) | JP5893640B2 (enExample) |
| KR (1) | KR20130133212A (enExample) |
| CN (1) | CN103270047A (enExample) |
| AU (1) | AU2011348396A1 (enExample) |
| BR (1) | BR112013016254A2 (enExample) |
| CA (1) | CA2822684A1 (enExample) |
| MX (1) | MX2013007146A (enExample) |
| WO (1) | WO2012084272A1 (enExample) |
| ZA (1) | ZA201304235B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE036158T2 (hu) | 2012-11-30 | 2018-06-28 | Glaxosmithkline Biologicals Sa | Pseudomonas antigének és antigén kombinációk |
| CN103983793A (zh) * | 2014-05-29 | 2014-08-13 | 上海理工大学 | 一种含丽春红的蛋白质芯片点样缓冲液及其制备方法 |
| BR112017003983A2 (pt) * | 2014-08-29 | 2018-02-14 | Sorrento Therapeutics Inc | ?terapêutica com anticorpos que se ligam a oprf e oprl? |
| CN107922482A (zh) | 2015-05-01 | 2018-04-17 | 英伊布里克斯有限合伙公司 | Iii型分泌系统靶向分子 |
| WO2016193402A1 (en) | 2015-06-03 | 2016-12-08 | Valneva Austria Gmbh | Pseudomonas vaccine |
| IL292037A (en) | 2015-07-16 | 2022-06-01 | Inhibrx Inc | Multivalent and multispecific dr5-binding fusion proteins and uses thereof |
| FR3099160B1 (fr) * | 2019-07-23 | 2022-05-06 | Univ Grenoble Alpes | Anticorps dirigé contre la protéine oprf depseudomonas aeruginosa, son utilisation en tant que médicament et composition pharmaceutique le contenant |
| WO2023236041A1 (zh) * | 2022-06-07 | 2023-12-14 | 南方科技大学 | 编码PcrV和/或OprF-I蛋白的mRNA疫苗 |
| CN116251178A (zh) * | 2023-03-28 | 2023-06-13 | 吉林农业大学 | 一种铜绿假单胞菌疫苗及其制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5494672A (en) * | 1989-04-28 | 1996-02-27 | S.P.I. Synthetic Peptides Incorporated | Pseudomonas peptide composition and method |
| ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
| ATE190657T1 (de) * | 1994-12-16 | 2000-04-15 | Chiron Behring Gmbh & Co | Immunogenes hybridprotein oprf-oprl erhältlich aus membranproteinen von pseudomonas aeruginosa |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US20040197341A1 (en) * | 2001-09-03 | 2004-10-07 | Jean-Claude Pechere | Therapeutic process for p. aeruginosa infections using macrolide antibiotics |
| ES2431318T3 (es) * | 2001-11-13 | 2013-11-26 | Id Biomedical Corporation | Polipéptidos de Pseudomonas aeruginosa |
| KR20120054644A (ko) * | 2003-01-15 | 2012-05-30 | 추가이 세이야쿠 가부시키가이샤 | 이량체화 펩티드 |
| US20070087331A1 (en) | 2003-05-15 | 2007-04-19 | Cytos Biotechnology Ag | Selection of b cells with specificity if interest: method of preparation and use |
| GB0410958D0 (en) * | 2004-05-15 | 2004-06-16 | Haptogen Ltd | Methods for reducing biofilm formation in infectious bacteria |
| JP2008524204A (ja) * | 2004-12-17 | 2008-07-10 | ヴィーナス・レメディーズ・リミテッド | 感染の処置に全面的解決を与えるための抗生物質の組合せ |
| EP1921142A1 (en) | 2006-11-07 | 2008-05-14 | Cytos Biotechnology AG | Selection of human monoclonal antibodies by eukaryotic cell display |
| HUE036158T2 (hu) * | 2012-11-30 | 2018-06-28 | Glaxosmithkline Biologicals Sa | Pseudomonas antigének és antigén kombinációk |
-
2011
- 2011-03-18 BR BR112013016254A patent/BR112013016254A2/pt not_active IP Right Cessation
- 2011-03-18 AU AU2011348396A patent/AU2011348396A1/en not_active Abandoned
- 2011-03-18 CA CA2822684A patent/CA2822684A1/en not_active Abandoned
- 2011-03-18 KR KR1020137015420A patent/KR20130133212A/ko not_active Ceased
- 2011-03-18 JP JP2013545118A patent/JP5893640B2/ja not_active Expired - Fee Related
- 2011-03-18 WO PCT/EP2011/054127 patent/WO2012084272A1/en not_active Ceased
- 2011-03-18 MX MX2013007146A patent/MX2013007146A/es not_active Application Discontinuation
- 2011-03-18 CN CN2011800625695A patent/CN103270047A/zh active Pending
- 2011-03-18 EP EP11714502.9A patent/EP2655402A1/en not_active Withdrawn
-
2013
- 2013-03-12 US US13/795,448 patent/US20130266575A1/en not_active Abandoned
- 2013-06-10 ZA ZA2013/04235A patent/ZA201304235B/en unknown
-
2016
- 2016-02-23 JP JP2016032315A patent/JP2016147867A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2655402A1 (en) | 2013-10-30 |
| ZA201304235B (en) | 2014-09-25 |
| BR112013016254A2 (pt) | 2017-07-11 |
| CN103270047A (zh) | 2013-08-28 |
| US20130266575A1 (en) | 2013-10-10 |
| JP2016147867A (ja) | 2016-08-18 |
| WO2012084272A1 (en) | 2012-06-28 |
| AU2011348396A2 (en) | 2013-07-11 |
| CA2822684A1 (en) | 2012-06-28 |
| JP2014504297A (ja) | 2014-02-20 |
| KR20130133212A (ko) | 2013-12-06 |
| JP5893640B2 (ja) | 2016-03-23 |
| AU2011348396A1 (en) | 2013-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013007146A (es) | Agentes de proteina f/i de membrana externa (oprf/i) y su uso en pacientes hospitalizados y otros pacientes. | |
| CU24058B1 (es) | Antagonistas de pcsk9 | |
| MX2015001399A (es) | Anticuerpos anti-etbr e inmunoconjugados. | |
| MX2012003939A (es) | Fusiones y conjugados de farmaco. | |
| CY1120413T1 (el) | Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου | |
| WO2010117760A3 (en) | Fusion proteins comprising canine fc portions | |
| WO2008121615A3 (en) | Antibody formulation | |
| CL2013003640A1 (es) | Proteina de union a il-17, construccion que comprende dicha proteina, un polipeptido ligador o un dominio constante de una inmunoglobulina; conjugado de dicha proteina; acido nucleico que la codifica; vector; celula huesped, metodo de produccion; composicion que la comprende; y su uso para reducir la actividad de la il-17 en una patologia en la cual il-17 es perjudicial (div.sol.2129-11). | |
| MX2009005414A (es) | Formulaciones liquidas de anticuerpo antirrabico. | |
| EA201171060A1 (ru) | Молекулы антител, обладающих специфичностью к человеческому ох40 | |
| MA35009B1 (fr) | Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci | |
| TW200745161A (en) | Stable antibody formulation | |
| AR075908A1 (es) | Formulacion farmaceutica que contiene moleculas de anticuerpo mejoradas, polipeptidos. metodo para estabilizar solucion, anticuerpo. | |
| MX2019003716A (es) | Formulaciones farmaceuticas de anticuerpos tnf-alfa. | |
| NZ711567A (en) | Antibody formulations | |
| NZ602220A (en) | Antibodies with ph dependent antigen binding | |
| CL2016000344A1 (es) | Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas | |
| WO2014028777A3 (en) | Methods of treating a tauopathy | |
| UY32609A (es) | Formulaciones estables de anticuerpos anti-tnf-alfa humanos con grandes concentraciones de proteína | |
| ES2564281T3 (es) | Formulación de anticuerpos Abeta | |
| EA201000018A1 (ru) | Лиофилизированные лекарственные формы иммуноглобулинов и способы их получения | |
| UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
| WO2011137243A3 (en) | Fluorescent fusion polypeptides and methods of use | |
| UA104933C2 (uk) | ЗЛИТИЙ ПОЛІПЕПТИД ПРОТИ ПУХЛИНИ, ІНДУКОВАНОЇ ВІРУСОМ EB, І МУТАНТ КОЛІЦИНУ Ia | |
| PH12014502352A1 (en) | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: BAYER INTELLECTUAL PROPERTY GMBH Owner name: MERCK SHARP & DOHME B.V. |
|
| FA | Abandonment or withdrawal |